These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2425014)

  • 1. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2.
    Yamamoto JK; Barré-Sinoussi F; Bolton V; Pedersen NC; Gardner MB
    J Interferon Res; 1986 Apr; 6(2):143-52. PubMed ID: 2425014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1.
    Sarin PS; Sun DK; Thornton AH; Naylor PH; Goldstein AL
    Science; 1986 May; 232(4754):1135-7. PubMed ID: 3010464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.
    Ho DD; Hartshorn KL; Rota TR; Andrews CA; Kaplan JC; Schooley RT; Hirsch MS
    Lancet; 1985 Mar; 1(8429):602-4. PubMed ID: 2857946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of the discovery of HTLV-III for the treatment of AIDS.
    Yarchoan R; Mitsuya H; Matsushita S; Broder S
    Cancer Res; 1985 Sep; 45(9 Suppl):4685s-4688s. PubMed ID: 2410113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.
    McDougal JS; Mawle A; Cort SP; Nicholson JK; Cross GD; Scheppler-Campbell JA; Hicks D; Sligh J
    J Immunol; 1985 Nov; 135(5):3151-62. PubMed ID: 2995487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of replication of the AIDS-associated virus HTLV-III/LAV by synthetic D-penicillamine.
    Chandra P; Sarin PS
    Arzneimittelforschung; 1986 Feb; 36(2):184-6. PubMed ID: 3008768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV).
    Balzarini J; Mitsuya H; De Clercq E; Broder S
    Int J Cancer; 1986 Mar; 37(3):451-7. PubMed ID: 2419266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of retroviral DNA polymerase: their implication in the treatment of AIDS.
    Chandra P; Vogel A; Gerber T
    Cancer Res; 1985 Sep; 45(9 Suppl):4677s-4684s. PubMed ID: 2410112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressive effects of interferons on the production and release of human T-lymphotropic virus type-I (HTLV-I).
    Oka T; Ohtsuki Y; Sonobe H; Furihata M; Miyoshi I
    Arch Virol; 1990; 115(1-2):63-73. PubMed ID: 1701080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro.
    Hartshorn KL; Neumeyer D; Vogt MW; Schooley RT; Hirsch MS
    AIDS Res Hum Retroviruses; 1987; 3(2):125-33. PubMed ID: 3113463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of growth of HIV by human natural interferon in vitro.
    Yamada O; Hattori N; Kurimura T; Kita M; Kishida T
    AIDS Res Hum Retroviruses; 1988 Aug; 4(4):287-94. PubMed ID: 3144996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct and cell-mediated effects of interferon-alpha and -gamma on cells chronically infected with HTLV-III.
    Dolei A; Fattorossi A; D'Amelio R; Aiuti F; Dianzani F
    J Interferon Res; 1986 Oct; 6(5):543-9. PubMed ID: 3100665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells.
    Ruscetti FW; Mikovits JA; Kalyanaraman VS; Overton R; Stevenson H; Stromberg K; Herberman RB; Farrar WL; Ortaldo JR
    J Immunol; 1986 May; 136(10):3619-24. PubMed ID: 2422259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral chemotherapies directed against HTLV-III/LAV.
    Resnick L
    Mt Sinai J Med; 1986 Dec; 53(8):648-56. PubMed ID: 3027545
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
    Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma).
    Zheng B; He ML; Wong KL; Lum CT; Poon LL; Peng Y; Guan Y; Lin MC; Kung HF
    J Interferon Cytokine Res; 2004 Jul; 24(7):388-90. PubMed ID: 15296649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral chemotherapy against HTLV-III/LAV infections.
    Oberg B
    J Antimicrob Chemother; 1986 May; 17(5):549-52. PubMed ID: 2424886
    [No Abstract]   [Full Text] [Related]  

  • 18. Recombinant human interferon gamma suppresses HTLV-III replication in vitro.
    Nakashima H; Yoshida T; Harada S; Yamamoto N
    Int J Cancer; 1986 Sep; 38(3):433-6. PubMed ID: 3017871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
    Montefiori DC; Robinson WE; Mitchell WM
    AIDS Res Hum Retroviruses; 1989 Apr; 5(2):193-203. PubMed ID: 2469450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.
    Sandstrom EG; Kaplan JC; Byington RE; Hirsch MS
    Lancet; 1985 Jun; 1(8444):1480-2. PubMed ID: 2409414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.